Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

The Brain Penetrant CDK4/6 Inhibitor, PRT3645, is Highly Effective in Combination with Other Targeted Therapies in Preclinical Models of Breast Cancer, CRC and NSCLC

Tuesday, April 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the effectiveness of PRT3645, a brain-penetrant CDK4/6 inhibitor, in combination with other targeted therapies. Preclinical models of breast cancer, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) show significant promise. This combination approach may enhance treatment efficacy for these cancers.
Price reaction · baseline $4.91 (2024-04-16 close) · hit after-hours · clean, no other PRLD news in the window
day 0 close
-14.9%
day 1 · peak
-29.9%
day 3
-21.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT3645 shows high effectiveness in preclinical models.
  • Combination therapies demonstrate promising results.
  • Targeted therapies could improve treatment outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Yue Zou, Kirsten Gallagher, Srijita Dhar, Andrew Buesking, Jack Carter, Anthony Reichelderfer, Jimin Park, Sarah Pawley, Ryan Holmes, Xiaowei Wu, Min Wang, Joseph Rager, Tom Emm, Stefan Ruepp, Bo Shen, Miles Cowart, Andrew Combs, Kris Vaddi, Sandy Geeganage, Peggy Scherle, Sang Hyun Lee

Frequently Asked Questions

What is PRT3645?

PRT3645 is a brain-penetrant CDK4/6 inhibitor used in cancer treatment.

In which cancers was PRT3645 tested?

PRT3645 was tested in preclinical models of breast cancer, CRC, and NSCLC.

How effective is PRT3645 in combination therapies?

PRT3645 shows high effectiveness when combined with other targeted therapies.

What types of therapies does PRT3645 combine with?

PRT3645 combines with various targeted therapies to enhance treatment outcomes.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3645 CDK4/6 inhibitor breast cancer NSCLC CRC
Last updated: Apr 16, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →